GAITHERSBURG, Md., June 5, 2023 /PRNewswire/ -- Novavax, Inc.
(Nasdaq: NVAX), a global company advancing protein-based vaccines
with its novel Matrix-M™ adjuvant, has signed a three-year
agreement with the Bill & Melinda Gates Medical Research
Institute to provide its adjuvant for use in preclinical
vaccine research.
"We are excited to partner with the Bill & Melinda Gates
Medical Research Institute to include our unique technology in
their public health-focused vaccine research efforts," said
John C. Jacobs, President and Chief
Executive Officer, Novavax. "Our Matrix-M™ adjuvant is proven to
enhance and broaden the immune system response when included in
vaccines and is already a key component of COVID and malaria
vaccines on the market today. We look forward to partnering more
broadly with a variety of organizations so that our technology can
benefit vaccine development across many disease areas."
"The Bill & Melinda Gates Medical Research Institute is
committed to developing biomedical interventions that address
global health concerns for those in the greatest need," said
Emilio Emini, PhD, chief executive
officer of the Bill & Melinda Gates Medical Research Institute.
"We look forward to working with Novavax's Matrix-M™ adjuvant
in some of our early-stage vaccine programs."
The Matrix-M adjuvant is a key component of Novavax's COVID
vaccine and its development-stage vaccines including influenza and
COVID and influenza combined. In addition, the adjuvant is being
used through partnerships in clinical and preclinical programs
across the world for the development of both human and animal
vaccines.
About Matrix-M™ Adjuvant
When added to vaccines,
Novavax's patented saponin-based Matrix-M adjuvant enhances the
immune system response, making it broader, and more durable. The
Matrix-M adjuvant stimulates the entry of antigen-presenting cells
at the injection site and enhances antigen presentation in local
lymph nodes.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to protect against serious infectious diseases.
Novavax, a global company based in Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. Focused on the
world's most urgent health challenges, Novavax is currently
evaluating vaccines for COVID, influenza, and COVID and influenza
combined. Please visit novavax.com and LinkedIn for more
information.
Forward-Looking Statements
Statements herein relating
to the future of Novavax, its operating plans and prospects, its
role in improving health globally, and its evaluation of vaccines
for COVID, influenza, and COVID and influenza combined, are
forward-looking statements. Novavax cautions that these
forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. These risks and
uncertainties include, without limitation, challenges satisfying,
alone or together with partners, various safety, efficacy, and
product characterization requirements, including those related to
process qualification and assay validation, necessary to satisfy
applicable regulatory authorities; difficulty obtaining scarce raw
materials and supplies; resource constraints, including human
capital and manufacturing capacity, on the ability of Novavax to
pursue planned regulatory pathways; unanticipated challenges or
delays in conducting clinical trials; challenges meeting
contractual requirements under agreements with multiple commercial,
governmental, and other entities; the emergence of variants of the
SARS-CoV-2 virus that may negatively impact market acceptance or
anticipated sales of NVX-CoV-2373; and those other risk factors
identified in the "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" sections
of Novavax's Annual Report on Form 10-K for the year ended
December 31, 2022 as filed with the
Securities and Exchange Commission (SEC). We caution investors not
to place considerable reliance on forward-looking statements
contained in this press release. You are encouraged to read our
filings with the SEC, available at www.sec.gov and
www.novavax.com, for a discussion of these and other risks
and uncertainties. The forward-looking statements in this press
release speak only as of the date of this document, and we
undertake no obligation to update or revise any of the statements.
Our business is subject to substantial risks and uncertainties,
including those referenced above. Investors, potential investors,
and others should give careful consideration to these risks and
uncertainties.
CONTACTS
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
Logo -
https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/novavax-announces-agreement-with-bill--melinda-gates-medical-research-institute-to-include-matrix-m-adjuvant-as-potential-component-in-vaccine-research-301841566.html